Characteristics of studies evaluating screening questionnaires (8 studies)13 22–25 27 28 38
| Characteristic | Range/number of studies | |
|---|---|---|
| Study designs | Cross-sectional test accuracy | 8 |
| Participants | 237–3158 | |
| Mean age (years) | 52.3–65.3 | |
| Male (%) | 38.1–69.0 | |
| Required smoking status | Only current/ex-smokers | 5 |
| Included never-smokers | 3 | |
| Required respiratory symptoms | 1 | |
| Setting | General practice(s) | 8 |
| Number of centres | 1–36 | |
| Multicentre | 7 | |
| Single centre | 1 | |
| Recruitment strategy | Active | 2 |
| Opportunistic | 3 | |
| Active and opportunistic | 2 | |
| Not reported | 1 | |
| Questionnaires | COPD Diagnostic Questionnaire* | 4 |
| Lung Function Questionnaire | 2 | |
| Not named | 2 | |
| Common items | ||
| Age | 7 | |
| Smoking status | 7 | |
| Respiratory symptoms | 8 | |
| Allergies | 5 | |
| Reference test—spirometry | ||
| Post-BD | 6 | |
| Definition of airflow obstruction | Post-BD FEV1/FVC <0.7 | 7 |
| Other† | 1 | |
| Included symptoms in definition of COPD | 1 | |
| Spirometry quality control | Yes | 8 |
| Range of results | ||
| Sensitivity | 57–93% | |
| Specificity | 24–80% | |
| Severity of new COPD cases | ≥80% | 11–39% |
| (FEV1% predicted)‡ | 50–80% | 43–61% |
| <50% | 10–37% | |
*Also referred to as the Respiratory Health Screening Questionnaire and the IPAG questionnaire.
†Pre-BD FEV1/FVC <88.5% predicted for men and FEV1/FVC <89.3% for women.
‡Based on five studies.
BD, bronchodilator; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; IPAG, International Primary Airways Group.